Phase I study of single-agent anti-programmed death-1 (MDX-1106) in refractory solid tumors: safety, clinical activity, pharmacodynamics, and immunologic correlates
单药抗程序性死亡-1 (MDX-1106) 治疗难治性实体瘤的 I 期研究:安全性、临床活性、药效学和免疫学相关性
期刊:Journal of Clinical Oncology
影响因子:42.1
doi:10.1200/JCO.2009.26.7609
Julie R Brahmer, Charles G Drake, Ira Wollner, John D Powderly, Joel Picus, William H Sharfman, Elizabeth Stankevich, Alice Pons, Theresa M Salay, Tracee L McMiller, Marta M Gilson, Changyu Wang, Mark Selby, Janis M Taube, Robert Anders, Lieping Chen, Alan J Korman, Drew M Pardoll, Israel Lowy, Suza